ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood
Open access · hybridAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
16.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Prognostic factors and outcomes in pediatric acute myeloid leukemia: a comprehensive bibliometric analysis of global research trends.Frontiers in oncology · 2025Pooled it
- Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013.Journal of hematology & oncology · 2026Trial
- Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist.HemaSphere · 2026Article
- Is the adult EBMT risk score valid and relevant for hematopoietic stem cell transplantation in children acute leukemia?Bone marrow transplantation · 2026Article
- Defining and managing high-risk acute myeloid leukemia (AML) in 2026.Annals of hematology · 2026Review
- Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.Blood advances · 2026Article
- Article
- Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic Developments.Cancers · 2026Review
- [Clinical characteristics and prognostic analysis of adult KMT2A-associated acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia.The FEBS journal · 2026Review
- Differential Modulation of JAK/STAT3 Signaling and BCL-2 Family Proteins by Tetracycline Analogues in Leukemia Models.Pharmaceutics · 2026Article
- Interplay between acute graft-versus-host disease and graft-versus-leukemia effect in pediatric acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: implications for relapse incidence and survival - an EBMT PDWP retrospective study.Bone marrow transplantation · 2026Article
- Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia.Frontiers in pharmacology · 2026Article
- Using genomics to refine pediatric AML risk stratification.Hematology. American Society of Hematology. Education Program · 2025Review
- Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party.British journal of haematology · 2025Article
- Prognostic Value of Molecular Genetic Measurable Residual Disease (MRD) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10.European journal of haematology · 2025Article
- The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia.Leukemia · 2025Review
- Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments.Journal of internal medicine · 2025Review
- A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in Acute Myeloid Leukemia.The Journal of molecular diagnostics : JMD · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
33 authors at 20 institutions in 16 countries.
Romy E van WeelderenPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0001-8485-5126
Kim KleinPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-9794-1071
Christine J HarrisonLeukemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom.
Yilin JiangPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Jonas AbrahamssonDepartment of Pediatrics, Institute of Clinical Sciences, Salgrenska University Hospital, Gothenburg, Sweden.
Nira Arad-CohenPediatric Hemato-Oncology Department, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.
Emmanuelle Bart-DelabesseIUC Toulouse-Oncopole, Laboratoire d'Hématologie secteur Génétique des Hémopathies, Toulouse, France.
Barbara BuldiniPediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padua University, Padua, Italy.ORCID 0000-0001-7285-2390
Barbara De MoerlooseDepartment of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-2449-539X
Michael N DworzakSt. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, and St Anna Children's Cancer Research Institute, Vienna, Austria.ORCID 0000-0002-8175-1097
Sarah ElitzurDepartment of Pediatric Hematology and Oncology, Schneider Children's Medical Center and Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-3495-7578
José M Fernández NavarroPediatric Oncohematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
Robert B GerbingDepartment of Statistics, The Children's Oncology Group, Monrovia, California.
Bianca F GoemansPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0003-4030-3228
Hester A de Groot-KrusemanPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Erin GuestChildren's Mercy Kansas City, Kansas City, MO.ORCID 0000-0003-2482-5608
Shau-Yin HaDepartment of Pediatrics & Adolescent Medicine, Hong Kong Children's Hospital, Kowloon, Hong Kong.ORCID 0000-0002-9191-8743
Henrik HaslePediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0003-3976-9231
Charikleia KelaidiDepartment of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece.
Hélène LapillonnePediatric Hematology and Oncology Department, Hôpital Armand Trousseau, Paris, France.
Guy LevergerPediatric Hematology and Oncology Department, Hôpital Armand Trousseau, Paris, France.
Franco LocatelliDepartment of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy.ORCID 0000-0002-7976-3654
Riccardo MasettiPediatric Oncology and Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy.ORCID 0000-0002-1264-057X
Takako MiyamuraDepartment of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.ORCID 0000-0002-3226-556X
Ulrika Norén-NyströmDepartment of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden.ORCID 0000-0001-5606-5442
Sophia PolychronopoulouDepartment of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece.
Mareike RascheDepartment of Pediatric Hematology and Oncology, University Hospital Essen, Essen, Germany.ORCID 0000-0002-7687-3655
Jeffrey E RubnitzDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-9885-3527
Jan StaryDepartment of Pediatric Hematology and Oncology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.ORCID 0000-0002-6818-7743
Anne TierensDepartment of Pathobiology and Laboratory Medicine, University Health Network, Toronto General Hospital, Toronto, ON, Canada.ORCID 0000-0002-5350-8313
Daisuke TomizawaChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
C Michel ZwaanPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0001-6892-8268
Gertjan J L KaspersPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0001-7716-8475
Princess Máxima Center · NLChildren's Hospital Agia Sophia · GREmma Kinderziekenhuis · NLSorbonne Université · FRAarhus University Hospital · DKAzienda USL di Bologna · ITCharles University · CZChildren's Mercy Hospital · USChildren's Oncology Group · USEssen University Hospital · DEGhent University Hospital · BEHospital Universitari i Politècnic La Fe · ESInstitut universitaire du cancer de Toulouse Oncopole · FRNational Center For Child Health and Development · JPNewcastle University · GBRambam Health Care Campus · ILSahlgrenska University Hospital · SESt Anna Children's Hospital · ATStichting Kinderoncologie Nederland · NLSt. Jude Children's Research Hospital · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MNCI NIH HHS U10 CA180886
Abstract
purposeA previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood
methodsA total of 1,130 children with
resultsThe high-risk group had inferior EFS (30.3% high risk
conclusionEOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood
Indexed as
Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyeloproliferative DisordersChildHumansNeoplasm, ResidualPrognosisRecurrenceTransplantation, Homologous
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.